A detailed history of Tower Research Capital LLC (Trc) transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 22,694 shares of SAGE stock, worth $115,739. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,694
Previous 13,929 62.93%
Holding current value
$115,739
Previous $151,000 7.95%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.02 - $13.08 $61,530 - $114,646
8,765 Added 62.93%
22,694 $163,000
Q2 2024

Aug 13, 2024

BUY
$10.58 - $17.9 $139,603 - $236,190
13,195 Added 1797.68%
13,929 $151,000
Q1 2024

May 15, 2024

SELL
$18.62 - $26.95 $54,631 - $79,071
-2,934 Reduced 79.99%
734 $13,000
Q4 2023

Feb 13, 2024

SELL
$17.1 - $22.26 $23,632 - $30,763
-1,382 Reduced 27.37%
3,668 $79,000
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $35,979 - $105,209
2,148 Added 74.02%
5,050 $103,000
Q2 2023

Aug 14, 2023

SELL
$40.65 - $59.54 $8,170 - $11,967
-201 Reduced 6.48%
2,902 $136,000
Q1 2023

May 09, 2023

BUY
$37.27 - $46.57 $83,261 - $104,037
2,234 Added 257.08%
3,103 $130,000
Q4 2022

Feb 10, 2023

SELL
$32.2 - $43.61 $326,830 - $442,641
-10,150 Reduced 92.11%
869 $33,000
Q3 2022

Nov 10, 2022

SELL
$32.28 - $43.27 $339,359 - $454,897
-10,513 Reduced 48.83%
11,019 $432,000
Q2 2022

Aug 15, 2022

BUY
$27.52 - $37.99 $75,349 - $104,016
2,738 Added 14.57%
21,532 $695,000
Q1 2022

May 12, 2022

BUY
$30.71 - $45.71 $277,188 - $412,578
9,026 Added 92.4%
18,794 $622,000
Q4 2021

Feb 14, 2022

BUY
$37.06 - $47.11 $141,013 - $179,253
3,805 Added 63.81%
9,768 $415,000
Q3 2021

Nov 15, 2021

BUY
$40.26 - $57.37 $203,997 - $290,693
5,067 Added 565.51%
5,963 $264,000
Q2 2021

Aug 16, 2021

SELL
$54.88 - $79.29 $5,268 - $7,611
-96 Reduced 9.68%
896 $51,000
Q1 2021

May 17, 2021

SELL
$70.65 - $96.76 $457,600 - $626,714
-6,477 Reduced 86.72%
992 $74,000
Q4 2020

Feb 16, 2021

BUY
$58.41 - $89.06 $326,920 - $498,468
5,597 Added 298.99%
7,469 $646,000
Q3 2020

Nov 16, 2020

SELL
$41.13 - $62.45 $89,622 - $136,078
-2,179 Reduced 53.79%
1,872 $114,000
Q2 2020

Aug 13, 2020

BUY
$25.95 - $43.15 $105,123 - $174,800
4,051 New
4,051 $168,000
Q1 2020

May 15, 2020

SELL
$26.15 - $77.24 $57,033 - $168,460
-2,181 Closed
0 $0
Q4 2019

Feb 07, 2020

BUY
$60.18 - $154.77 $102,967 - $264,811
1,711 Added 364.04%
2,181 $157,000
Q3 2019

Nov 05, 2019

SELL
$140.29 - $189.96 $19,360 - $26,214
-138 Reduced 22.7%
470 $66,000
Q2 2019

Aug 13, 2019

BUY
$157.85 - $183.09 $95,972 - $111,318
608 New
608 $111,000
Q4 2018

Feb 14, 2019

SELL
$81.94 - $139.71 $9,505 - $16,206
-116 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$138.11 - $169.04 $64,359 - $78,772
-466 Reduced 80.07%
116 $16,000
Q2 2018

Aug 15, 2018

BUY
$140.36 - $175.76 $81,689 - $102,292
582 New
582 $91,000
Q4 2017

Feb 09, 2018

SELL
$60.72 - $167.34 $335,478 - $924,553
-5,525 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$61.4 - $88.52 $339,235 - $489,073
5,525
5,525 $344,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $303M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.